Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
American Heart Association (AHA) Scientific Sessions 2018
November 10 - 12, 2018; Chicago, Illinois
November 10 - 12, 2018Chicago, Illinois
AHA 2018ENCORE-VT Takes Noninvasive VT Ablation to Next LevelAfter posting remarkable results with stereotactic radiation in a handful of salvage refractory-VT cases, a prospective study yields similarly dazzling results.
Medscape Medical News, November 14, 2018
AHA 2018REDUCE-IT: 'A New Era' in CVD Prevention With High-Dose EPA High doses of a purified form of the omega-3 oil, eicosapentaenoic acid, showed a large, robust reduction in events, opening an exciting new avenue for CVD prevention, researchers say.
Medscape Medical News, November 10, 2018
AHA 2018New AHA/ACC Cholesterol Guideline Expands Role of LDL Targets An update to the controversial 2013 guidelines retains key elements but also puts less weight on estimated 10-year ASCVD risk and emphasizes contemporary ideas, such as shared decision-making.
Medscape Medical News, November 10, 2018
Meeting Highlights At A Glance
Top News From AHA 2018: SlideshowHighlights include new guidelines on cholesterol management and physical activity, plus potentially practicing changing results
with high-dose omega-3 for CVD prevention.
Think You're Immune From Bias? Think AgainJohn Mandrola, MD, is intrigued by two studies at AHA that track the cognitive and financial biases that may influence what
physicians do in practice and how they write and read research papers.
ENCORE-VT: Noninvasive Ablation of VT Could Disrupt EPA small study suggests that ventricular arrhythmia may be treated without the need for catheters and anesthesia. John Mandrola,
MD, is impressed with the findings and the investigators' lack of hyperbole.
Pure Fish Oil Lowers CVD Risk Even If We Don’t Understand HowREDUCE-IT found that high-dose purified omega-3 fish oil reduced CV events even if the drug didn’t work as expected. Evidence-based
practice means we should embrace these results, says John Mandrola, MD.
Mandrola Previews AHA 2018Among the highlights for the upcoming American Heart Association Scientific Sessions are studies on omega-3, inflammation,
a potential EP breakthrough, and yoga. Not to mention new lipid guidelines.
What's Needed After AHA 2018? ACTIONA sparsely attended session on social determinants of health sounded very familiar to Melissa Walton-Shirley, MD. So if we
know what to do to improve CV health, why haven’t we done it yet?
Glad Your EF Is Better, But Stay on Your MedsWhile the TRED-HF trial may not be great news for patients with dilated cardiomyopathy and recovered EF, at least it eases
this physician's conscience about her reluctance to curtail pharmacotherapy.
Lipid Lollapalooza at AHA 2018The release of the 2018 cholesterol guidelines and a bunch of lipid-oriented trials made it a bountiful day at the American
Heart Association meeting for Melissa Walton-Shirley, MD
Popular News from AHA 2017
New ACC/AHA Hypertension Guidelines Make 130 the New 140New guidelines endorsed by 11 organizations lower the threshold for stage 1 hypertension to include adults with systolic pressure
from 130 to 139 mm Hg or 80 to 89 mm Hg diastolic.
Medscape Medical News, Nov 13, 2017
TRICS-3 Disputes 'Liberal' RBC Transfusions at Cardiac Surgery"Blood is expensive and blood is toxic," points out an observer of the largest-yet trial looking at the issue: good reasons
to avoid transfusions in cardiac surgery only to keep hemoglobin levels high.
Medscape Medical News, Nov 12, 2017
DACAB: Ticagrelor Plus Aspirin Improves CABG Graft PatencyResults showed dual therapy with aspirin and ticagrelor resulted in improved patency of saphenous vein grafts vs either agent
alone, but the data are unlikely to change practice yet, observers say.